A cyberattack on Change Healthcare disrupted patient scheduling, billing, and potentially exposed patient data. It caused financial strain on medical practices and took weeks to recover from.
John M. Burke, MD
Hematologist and Medical Oncologist
Rocky Mountain Cancer Centers
Associate Chair
US Oncology Hematology Research Program
Aurora, CO
February 21, 2024, seemed like any other Wednesday, but during the day, word spread around the office that the software program athenaOne, which we use to schedule patients, was not working. This was not the first time that athenaOne had malfunctioned, but this time it went down and stayed down. Eventually, the explanation became clear: Change Healthcare, a subsidiary of Optum and owned by UnitedHealth Group, announced that its network had been the victim of a cyberattack.
The company’s technology also processes insurance claims, including billions of prescriptions annually. Clearly, a disruption to the Change Healthcare systems could be catastrophic to the entire US health care system.
A group known as either “ALPHV” or “BlackCat” orchestrated the cyberattack. BlackCat reportedly functions as a “ransomware-as-a-service” organization, meaning that its leadership develops ransomware, which affiliates of BlackCat deploy to attack a company. Any subsequent ransom payments are divided between the BlackCat leadership and the affiliates. UnitedHealth Group is believed to have paid a $22 million ransom to BlackCat, although the company has not confirmed this. In addition to paying the ransom, in April, UnitedHealth Group announced that the cyberattack had cost it $872 million, with the projected total cost for the year ranging between $1.35 billion and $1.6 billion.
Recently, a new hacker group called RansomHub said it had 4 terabytes of data from Change Healthcare and demanded another ransom payment. On April 16, 2024, RansomHub delivered on its threat and posted patient health and other confidential information, including contracts between Change Healthcare and its clients, on its dark website.
After about 6 weeks, our practice was able to return closer to business as usual, and the scheduling software is now functional. However, during the crisis, our staff had to create work-arounds to schedule patients and after systems were restored, we had to catch up on unbilled charges. The damage to physician practices may be extensive. A survey by the American Medical Association found that 80% of physicians reported lost revenue because of the event. I know my practice counts itself in that category, and we are still working to estimate the damage done.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More